Literature DB >> 27621510

Sacubitril/Valsartan.

Dennis J Cada1, Danial E Baker2, James Leonard2.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The December 2015 monograph topics are rolapitant, insulin degludec, flibanserin, coagulation factor IX (recombinant), and grazoprevir/elbasvir. The Safety MUE is on rolapitant.

Entities:  

Year:  2015        PMID： 27621510      PMCID： PMC4750837          DOI： 10.1310/hpj5011-1025

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  18 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Kazuomi Kario; Ningling Sun; Fu-Tien Chiang; Ouppatham Supasyndh; Sang Hong Baek; Akiko Inubushi-Molessa; Ying Zhang; Hiromi Gotou; Martin Lefkowitz; Jack Zhang
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

3.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

4.  Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.

Authors:  Pardeep S Jhund; Brian L Claggett; Adriaan A Voors; Michael R Zile; Milton Packer; Burkert M Pieske; Elisabeth Kraigher-Krainer; Amil M Shah; Margaret F Prescott; Victor Shi; Marty Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2014-10-02       Impact factor: 8.790

5.  Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.

Authors:  Lu Gan; Thomas Langenickel; Jesika Petruck; Kiran Kode; Iris Rajman; Priya Chandra; Wei Zhou; Sam Rebello; Gangadhar Sunkara
Journal:  J Clin Pharmacol       Date:  2015-08-24       Impact factor: 3.126

6.  Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.

Authors:  Akshay S Desai; John J V McMurray; Milton Packer; Karl Swedberg; Jean L Rouleau; Fabian Chen; Jianjian Gong; Adel R Rizkala; Abdel Brahimi; Brian Claggett; Peter V Finn; Loren Howard Hartley; Jiankang Liu; Martin Lefkowitz; Victor Shi; Michael R Zile; Scott D Solomon
Journal:  Eur Heart J       Date:  2015-05-28       Impact factor: 29.983

7.  Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors:  Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal:  J Clin Pharmacol       Date:  2009-11-23       Impact factor: 3.126

8.  Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.

Authors:  Pardeep S Jhund; Brian Claggett; Milton Packer; Michael R Zile; Adriaan A Voors; Burkert Pieske; Martin Lefkowitz; Victor Shi; Toni Bransford; John J V McMurray; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2014-04-01       Impact factor: 15.534

9.  Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Authors:  Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong
Journal:  Circulation       Date:  2014-11-17       Impact factor: 29.690

10.  A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.

Authors:  John McMurray; Milton Packer; Akshay Desai; Jianjian Gong; Nicola Greenlaw; Martin Lefkowitz; Adel Rizkala; Victor Shi; Jean Rouleau; Scott Solomon; Karl Swedberg; Michael R Zile; Karl Andersen; Juan Luis Arango; Malcolm Arnold; Jan Bĕlohlávek; Michael Böhm; Sergey Boytsov; Lesley Burgess; Walter Cabrera; Chen-Huan Chen; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzalez; Albert-Alain Hagege; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Edmundo Bayram; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix Ramires; Jens Refsgaard; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain Squire; Randall C Starling; Dragos Vinereanu; John R Teerlink; Raymond Wong
Journal:  Eur Heart J       Date:  2015-02-14       Impact factor: 29.983
View more
  2 in total

Review 1.  Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination.

Authors:  Edgardo Kaplinsky
Journal:  J Geriatr Cardiol       Date:  2016-11       Impact factor: 3.327

Review 2.  Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Pooja Dewan; Kieran F Docherty; John J V McMurray
Journal:  Korean Circ J       Date:  2019-06       Impact factor: 3.243
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.